The third report under Article 111(3) on REACH is covering data on over substances, concluding that with more than 6 000 substances submitted, alternatives animal testing were widely used. 6 290 substances were analysed for the report. Out of these, 89 % have at least one data endpoint where an alternative was used instead of a study on animals. Read across with information on similar substances was prefered for 60% of the substances analysed, but the report highlight the fact that oftenly registrants didn’t provide enough scientific evidence to support their read across case.

ECHA promote the use of appropriate in vitro methods, including new high throughput assessment methods, which can “provide more human revelant information”. Toxicity assays provided by HCS Pharma are developed on our high throughput platform, allows analysing toxic events, as genotoxicity, hepatotoxicity, neurotoxicity or cardiotoxicity for your information requested by ECHA.

Options that registrants use to cover REACH information requirements for different data endpoints

Source : The use of alternatives to testing on animals for the REACH Regulation